Market Overview

Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod

Related CELG
Benzinga's Top Upgrades, Downgrades For May 5, 2017
Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?

Celgene Corporation (NASDAQ: CELG) shares are trading higher by $2.00 at $120.66 in Friday's session. The catalyst for the rally is a Phase II study of Oral Ozanimod with relapsing MS meeting its primary endpoint in reducing ARR, measured endpoints.

After a higher open, it had a brief retreat but found found support just under above Thursday's close ($118.66), only reaching $118.81 before continuing its move higher.

So far, the ensuing rally has cleared the pair of highs from Wednesday ($120.63) and Thursday ($120.77), reaching $120.90. If the rally continues, the next resistance daily resistance point comes in at its January 19 high of $121.59.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (CELG)

View Comments and Join the Discussion!